Pharming Group to report third quarter 2024 financial results on October 24

Rhea-AI Summary

Pharming Group N.V. (Euronext Amsterdam: PHARM/Nasdaq: PHAR) has announced that it will release its preliminary (unaudited) third quarter 2024 financial results on Thursday, October 24, 2024. The results will cover the period ended September 30. The company will host a presentation for analysts and investors at 13:30 CEST/07:30 am EDT on the same day.

To participate in the conference call, interested parties must register in advance using the provided link. Upon registration, dial-in information and a unique PIN will be provided for call access. The company will only take questions from dial-in attendees. Additionally, a live webcast of the presentation will be available, with a separate registration link provided for those who wish to watch online.

Leiden, the Netherlands, October 10, 2024: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) confirms it will report its preliminary (unaudited) third quarter 2024 financial results, for the period ended September 30, on Thursday, October 24, 2024.

Pharming will host a presentation for analysts and investors at 13:30 CEST/07:30 am EDT on October 24, 2024.

To participate in the conference call, please register in advance using the link below. Once registered, dial-in information and a unique PIN will be provided, allowing access to the call.

Conference call registration:
Please note, the Company will only take questions from dial-in attendees.

https://register.vevent.com/register/BId118ac68d9124f67b1a83e3769559100

To watch the live webcast, please register in advance using the link below.

Webcast registration:

https://edge.media-server.com/mmc/p/yotjk8ib

About Pharming Group N.V.
Pharming Group N.V. (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases. Pharming is commercializing and developing an innovative portfolio of protein replacement therapies and precision medicines, including small molecules and biologics. Pharming is headquartered in Leiden, the Netherlands, and has employees around the globe who serve patients in over 30 markets in North America, Europe, the Middle East, Africa, and Asia-Pacific.

For more information, visit www.pharming.com and find us on LinkedIn.

For further public information, contact:

Pharming Group, Leiden, the Netherlands
Michael Levitan, VP Investor Relations & Corporate Communications
T: +1 (908) 705 1696
E: investor@pharming.com

FTI Consulting, London, UK
Victoria Foster Mitchell/Alex Shaw/Amy Byrne
T: +44 203 727 1000

LifeSpring Life Sciences Communication, Amsterdam, the Netherlands
Leon Melens
T: +31 6 53 81 64 27
E: pharming@lifespring.nl

Attachment

• Pharming Group to report 3Q24 results_EN_10OCT24

FAQ

When will Pharming Group report its Q3 2024 financial results?

Pharming Group will report its preliminary (unaudited) third quarter 2024 financial results on Thursday, October 24, 2024.

What period will Pharming's Q3 2024 financial results cover?

The financial results will cover the period ended September 30, 2024.

What time is Pharming's Q3 2024 earnings presentation scheduled for?

Pharming will host a presentation for analysts and investors at 13:30 CEST/07:30 am EDT on October 24, 2024.

How can investors participate in Pharming's Q3 2024 earnings call?

Investors must register in advance using the provided link. Once registered, they will receive dial-in information and a unique PIN for call access.

Will there be a webcast available for Pharming's Q3 2024 earnings presentation?

Yes, a live webcast will be available. Interested parties can register in advance using the provided webcast registration link.